Skin cancer

A student-led teledermatology-dermoscopy initiative that identified skin lesions in underserved communities could be a scalable model for early skin cancer detection and care.

FDA-cleared DermaSensor device shows 96% sensitivity and reduces missed skin cancer diagnoses by 50% in primary care, according to new data.

Results showed that a nanoencapsulated CBD cream reduced UV-A–induced nuclear and mitochondrial DNA damage linked to photoaging in human skin.

Dermatologist Rebecca Hartman, MD, MPH, said that reliable point-of-care screening results can help reduce unnecessary specialist referral for benign lesions.

The DermaSensor skin cancer screening device was pitted against clinical impressions of lesions suspected with high confidence to be melanoma. Results, here.

Dermatologists at high volume dermatology centers referred suspicious lesions to pathology for biopsy and diagnosis. The results were compared with DermaSensor read-outs.

Nicotinamide may lower the incidence of new nonmelanoma skin cancers in patients at high risk for skin cancer, providing a new chemopreventive opportunity.